Last updated: May 26, 2026
CILOXAN is a brand of ciprofloxacin ophthalmic solution/ointment marketed for ocular infections. Supplier visibility is typically split across (1) the marketing authorization holder/brand owner and (2) manufacturers of record listed on the product label and in FDA ownership/manufacturing data, plus (3) distribution through national pharmaceutical wholesalers and specialty channels.
What suppliers make CILOXAN (ciprofloxacin ophthalmic) in the US?
Answer: The practical supplier set for CILOXAN in the US is the set of manufacturers of record shown on the FDA label for each dosage form and strength, with distribution via standard pharmaceutical wholesale networks.
Which entities appear as manufacturer/distributor of record on the label?
For label-based sourcing, CILOXAN typically routes through:
- Labeler/marketer (brand owner in the US): the firm listed as the product’s labeler
- Manufacturer of record: the contract or company plant that produces the drug substance or the finished ophthalmic product
- Distributor/shipper: sometimes a separate affiliate or logistics/distribution company named on packaging or label sections
Because manufacturer-of-record status is product-form specific (solution vs ointment) and strength specific, supplier identification should be performed at the SKU level (NDC level), not only at the molecule level (ciprofloxacin).
Who is the marketing authorization holder for CILOXAN?
Answer: Identify the labeler on the FDA drug label for each CILOXAN NDC. That entity controls US commercial supply and is usually the legal party for product submissions and labeling, even when production is contract-manufactured.
How does labeler status affect supply chain and licensing?
- The labeler is the counterparty used for most supply and regulatory interfaces: lot release, labeling changes, and regulatory correspondence.
- The manufacturer of record is the counterparty for manufacturing scale-up, inspection readiness, and compliance questions tied to cGMP production.
Which NDCs should sourcing teams use to map CILOXAN suppliers?
Answer: Use NDC-level mapping because supplier changes can occur by lot release manufacturing site, packaging configuration, or strength.
How to build an NDC-to-supplier matrix
A supplier matrix should include, per NDC:
- Labeler
- Manufacturer of record
- Dosage form (solution vs ointment)
- Strength
- Package type (bottle size or tube size)
- Route for distribution (direct vs through wholesalers)
This avoids mixing different supply sources for the same brand.
What manufacturers produce ciprofloxacin ophthalmic solutions and ointments under CILOXAN?
Answer: CILOXAN is commonly produced through either:
- branded manufacturing by the labeler, or
- CDMO / contract manufacturing for ophthalmic sterile products, which is then finished and labeled under the brand.
What to check in supplier due diligence
For sterile ophthalmics, the supplier’s certification and plant approvals are the gating items:
- FDA establishment registration tied to the manufacturer of record
- cGMP compliance history for sterile ophthalmic manufacturing
- Sterility assurance approach (aseptic processing and environmental monitoring program)
- Change-control history for formulation, container/closure system, and filling lines
Who distributes CILOXAN in the US wholesale channel?
Answer: Distribution is generally routed through the standard US pharmaceutical wholesaler network, with ordering handled at pharmacy and health-system procurement levels based on NDC availability.
Typical distribution model for branded ophthalmics
- National wholesalers carry inventory and facilitate replenishment
- Specialty distributors may handle segments where ophthalmic supply is constrained
- Contract distribution may be used during shortages or targeted hospital supply contracts
Supplier identification for distribution should be pulled from the chain-of-custody documentation used by procurement (purchase orders, invoices, and lot traceability), not from brand-level assumptions.
Does CILOXAN have biosimilar or generic supplier competition?
Answer: No biosimilar issue applies because ciprofloxacin ophthalmic is a small-molecule drug. The competitive pressure is from generics and authorized equivalents of ciprofloxacin ophthalmic solution and ointment.
What supplier risk exists from generic entrants?
- Reduced share for the brand can lead to supply reallocation by the labeler
- In shortage periods, brand supply may be protected while generic supply fluctuates, affecting which manufacturers get prioritized
How do you identify alternate suppliers if CILOXAN shortages occur?
Answer: The alternate suppliers that matter are the alternate manufacturing sites and alternate packaging/labeling configurations for CILOXAN tied to NDC changes.
Practical shortage playbook for sourcing teams
- Switch to the NDCs that preserve the same labeled strengths/dosage form and container/closure compatibility
- Verify the manufacturer of record on the specific lot/pack
- Confirm chain-of-custody and lot traceability before purchase, especially during high-demand periods
What patent and exclusivity status affects CILOXAN supply?
Answer: Supply for an ophthalmic ciprofloxacin brand is affected more by manufacturing capacity and cGMP compliance than by biologic exclusivity. Market exclusivity and patent protection affect competitive pricing and availability, but not the immediate ability to produce unless the product is tied to specific protected formulation or method-of-use claims.
How supplier planning typically maps to patent estates (overview)
- If a labeler’s branded formulation is protected, generics can still enter with non-infringing formulations or other carve-outs depending on Orange Book listings
- For sterile ophthalmics, litigation risk usually influences market entry timing more than it changes upstream CDMO qualification
Key suppliers for CILOXAN: what the sourcing deliverable should list
A sourcing deliverable suitable for procurement and regulatory audit should list, by dosage form and NDC:
| Data field |
Why it matters |
| Labeler / brand owner |
Legal counterparty for regulatory and labeling |
| Manufacturer of record (plant) |
Direct cGMP manufacturer for that SKU |
| Dosage form |
Sterile process and facility fit differ |
| Strength and packaging |
Different NDCs can shift suppliers |
| Distribution channel |
Impacts lead time and lot traceability |
| Lot release source |
Controls recall readiness and QA verification |
Key Takeaways
- CILOXAN supplier identification should be done at the NDC level, not just by drug name.
- The supplier set is primarily the labeler/brand owner plus the manufacturer of record for each dosage form and strength, with distribution handled through standard wholesale channels.
- During shortages, the actionable supplier changes are typically alternate manufacturing sites and alternate packaging configurations tied to specific NDCs and lots.
FAQs
1) How can I find the manufacturer of record for CILOXAN for a specific bottle or tube size?
Use the NDC on the carton and read the manufacturer/distributor sections on the FDA label tied to that NDC.
2) Are CILOXAN solution and CILOXAN ointment made by the same supplier?
Not necessarily. Manufacturers can differ by dosage form because sterile processing lines and filling configurations are often plant-specific.
3) What supplier documentation is required for sterile ophthalmic procurement (cGMP and QA)?
At minimum: lot traceability, certificate of analysis, cGMP compliance statements tied to the manufacturer of record, and recall/complaint contact details from labeler packaging.
4) Do generic ciprofloxacin ophthalmic products change my supply chain for CILOXAN?
Yes. Generic availability influences whether the labeler can throttle brand production versus reallocating capacity, and it changes lead times through NDC substitution.
5) What is the fastest way to re-source CILOXAN during lead-time disruptions?
Switch across equivalent NDCs that keep strength and dosage form consistent, then confirm the manufacturer of record for the specific lot before release.
References (APA)
- FDA. (n.d.). Drug labels and product information for CILOXAN (ciprofloxacin ophthalmic). U.S. Food and Drug Administration.
